2023 annual financial data
Supernus Pharmaceuticals 2023 Operating margin
Supernus Pharmaceuticals 2023 operating margin with verified reported values.
Direct answer
Operating margin was -0.87%.
Operating income was -5,269,000 USD and net income was 1,316,000 USD.
Operating cash flow was 111,085,000 USD.
Get free Supernus Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 607,521,000 USD
- Operating income
- -5,269,000 USD
- Net income
- 1,316,000 USD
- Operating cash flow
- 111,085,000 USD